Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04608344 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT04608344 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 27 participants.
The verdict
NCT04608344, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of filgotinib on a mixed organic anion transporting polypeptide/cytochrome P450 3A (OATP/CYP3A), OATP/ breast cancer resistance protein (BCRP), and OATP substrates using phenotypic probes.
Interventions
- DRUG Rosuvastatin
- DRUG Atorvastatin
- DRUG Pravastatin
- DRUG Filgotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-11-04 |
| Est. Completion | 2021-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04608344
The ClinicalTrials.gov registry entry for NCT04608344 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rosuvastatin is the first listed.
NCT04608344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04608344 about?
NCT04608344 is a clinical study titled "Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants". The primary objective of this study is to evaluate the effect of filgotinib on a mixed organic anion transporting polypeptide/cytochrome P450 3A (OATP/CYP3A), OATP/ breast cancer resistance protein (BCRP), and OATP substrates using phenotypic probes.
What is the current status of trial NCT04608344?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2020-11-04. Estimated completion is 2021-01-13.
What interventions are being tested in trial NCT04608344?
The interventions under investigation include: Rosuvastatin (DRUG), Atorvastatin (DRUG), Pravastatin (DRUG), Filgotinib (DRUG).
Who is sponsoring clinical trial NCT04608344?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.